# 17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

> **NCT00163020** · PHASE2,PHASE3 · COMPLETED · sponsor: **Obstetrix Medical Group** · enrollment: 321 (actual)

## Conditions studied

- Preterm Birth

## Interventions

- **DRUG:** 17-alpha-hydroxyprogesterone caproate injectable
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00163020
- **Lead sponsor:** Obstetrix Medical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2016-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163020, "17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00163020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*